Learning outcomes
By the end of this lesson you should be able to: explain blood pressure as cardiac output multiplied by total peripheral resistance and identify which term of that equation each antihypertensive class lowers; name the first-line classes — thiazide-like diuretics, calcium-channel blockers, ACE inhibitors and ARBs — and explain when a beta-blocker is added for a compelling indication; state the mechanism, principal indication and characteristic adverse effects of each class; predict the drug interactions that make combinations safe or unsafe, such as verapamil with a beta-blocker; and outline the management of a hypertensive emergency with titratable intravenous agents.
Prerequisites
Lessons 1 to 6, above all autonomic pharmacology (beta-blockers, alpha-blockers) and the cardiovascular module of the physiology course.
The big idea
Hypertension damages the body silently through pressure itself: left ventricular hypertrophy progressing to heart failure, stroke and small-vessel cerebral disease, atherothrombosis and aneurysm formation, chronic kidney disease with proteinuria, and hypertensive retinopathy. The trial benefit of treating it is large, and most classes lower the pressure by a similar modest amount, so the choice of first drug is driven less by efficacy at the pressure alone and more by comorbidity, age, ethnicity, tolerability and cost. Two agents used together, each from a different pathway, lower the pressure far more than doubling the dose of one.
The classes at a glance
| Class | Example drugs | Mechanism | Term of the equation lowered |
|---|---|---|---|
| Thiazide and thiazide-like diuretics | Indapamide, chlortalidone, bendroflumethiazide | Inhibit the sodium-chloride cotransporter in the distal convoluted tubule, reducing sodium reabsorption and, with time, peripheral resistance | Output at first, resistance with chronic use |
| Dihydropyridine calcium-channel blockers | Amlodipine, lercanidipine, nifedipine | Block L-type calcium channels in vascular smooth muscle, dilating arterioles | Resistance |
| Non-dihydropyridine calcium-channel blockers | Verapamil, diltiazem | Block calcium channels in the SA and AV nodes and myocardium, slowing rate and contractility | Output |
| ACE inhibitors | Ramipril, lisinopril, enalapril | Block angiotensin-converting enzyme, lowering angiotensin II and raising bradykinin | Resistance (afterload and aldosterone) |
| Angiotensin receptor blockers | Losartan, valsartan, candesartan | Block the angiotensin II AT1 receptor directly, leaving bradykinin untouched | Resistance |
| Beta-blockers | Bisoprolol, atenolol, carvedilol | Block beta-1 receptors, reducing heart rate, contractility and renin release | Output (and renin-driven resistance) |
| Alpha-1 blockers | Doxazosin, prazosin | Block alpha-1 mediated vasoconstriction | Resistance |
ACE inhibitors and ARBs
| Agent | Mechanism detail | Characteristic adverse effects |
|---|---|---|
| Ramipril, lisinopril | Reduce angiotensin II, so vasoconstriction and aldosterone-driven sodium retention fall; bradykinin accumulates because the same enzyme degrades it | Persistent dry cough, angioedema, hyperkalaemia, first-dose hypotension, modest creatinine rise, teratogenic |
| Valsartan, losartan, candesartan | Block the AT1 receptor for angiotensin II without interfering with bradykinin | Hyperkalaemia, renal impairment, teratogenic, but no cough or angioedema from bradykinin |
Both classes raise creatinine modestly and predictably at initiation, because they dilate the efferent arteriole of the glomerulus; a rise of up to about thirty per cent is expected and is not a reason to stop. They are dangerous in bilateral renal artery stenosis, where the whole filtration pressure depends on angiotensin-mediated efferent tone. The combination of an ACE inhibitor with an ARB adds renal risk without benefit, so it is not prescribed, and both classes are contraindicated in pregnancy.
NoteThe dry cough of an ACE inhibitor is bradykinin-mediated, and it is the reason an ARB is substituted: the ARB keeps the angiotensin blockade but spares the bradykinin, so the cough resolves. Angioedema is rare but life-threatening by the same mechanism, and once it has occurred every ACE inhibitor is contraindicated thereafter, not merely the one that caused it.
Calcium-channel blockers
| Agent | Cardiac effect | Vascular effect | Typical adverse effect |
|---|---|---|---|
| Amlodipine (dihydropyridine) | Reflex tachycardia | Powerful arteriolar dilation | Ankle oedema from capillary leak, flushing, headache, gingival hyperplasia |
| Verapamil (non-dihydropyridine) | Slows the SA and AV nodes, reduces contractility | Milder dilation | Constipation, bradycardia, precipitation of heart block |
| Diltiazem (non-dihydropyridine) | Slows nodal conduction | Moderate dilation | Bradycardia, conduction disturbances |
Watch outAnkle oedema from amlodipine is leakage from the raised pressure in the dilated precapillary arteriole — not sodium and water retention. It does not respond to a diuretic, which wastes electrolyte without touching the swelling; reduce the dose or pair with a RAS blocker, whose venodilation offsets the leak. Verapamil plus a beta-blocker is the opposite trap: both slow the AV node and together risk complete heart block and profound bradycardia.
Beta-blockers and resistant hypertension
Beta-blockers are less effective as monotherapy in older patients and in those of African or Caribbean family origin, and they carry metabolic and quality-of-life costs (fatigue, erectile dysfunction, masking of hypoglycaemia, worsening of insulin sensitivity). They earn their place with a compelling indication: angina, post-myocardial-infarction, heart failure with reduced ejection fraction, rate control in atrial fibrillation, or thyrotoxicosis. Spironolactone is the evidence-based fourth-line agent for resistant hypertension on three drugs, because aldosterone-driven sodium retention and hypertension are now recognised as common; it is added with careful potassium monitoring.
Hypertensive emergency and urgency
A hypertensive emergency is a very high blood pressure with acute target-organ damage — pulmonary oedema, stroke, aortic dissection, myocardial ischaemia, acute kidney injury or eclampsia. It demands admission and a titratable intravenous agent monitored against an arterial line, because the organs have autoregulated to the elevated pressure and an abrupt fall produces watershed infarction. A severe elevation without target-organ damage is an urgency: it is treated with oral agents and rapid outpatient review, not by an emergency department infusion.
| Intravenous drug | Action | Preferred when |
|---|---|---|
| Labetalol | Combined alpha and beta blockade, lowering resistance and heart rate together | The usual first choice in most emergencies, and specifically aortic dissection after beta-blockade |
| Hydralazine | Direct arteriolar dilation with reflex tachycardia | Eclampsia (after magnesium sulfate) or pregnancy-associated hypertension |
| Glyceryl trinitrate | Predominantly venodilation with coronary dilation | Pulmonary oedema with associated ischaemia |
| Nicardipine, clevidipine | Short-acting dihydropyridine infusions | Where smooth, predictable titration is required |
| Nitroprusside | Arterial and venous dilation with cyanide accumulation risk | Rarely now, and only for brief use in refractory crises |
Common mistakes
Watch outTreating amlodipine-induced ankle oedema with furosemide. The oedema is capillary leakage from arteriolar dilation, not sodium retention, so the diuretic makes the patient hypokalaemic without reducing the swelling. Lower the dose or pair with a RAS blocker.
Watch outCombining an ACE inhibitor with an ARB. Alone each has outcome benefit; together they compound hyperkalaemia and renal impairment, and the trials of dual renin-angiotensin blockade were stopped early for harm.
Watch outCalling beta-blockade first-line for uncomplicated hypertension. Current guidelines reserve first place for a calcium-channel blocker, a thiazide-like diuretic or an ACE inhibitor or ARB; older atenolol-based regimens showed inferior outcomes.
Watch outForgetting pregnancy. Both ACE inhibitors and ARBs are teratogenic — oligohydramnios and fetal renal failure — so they are stopped and replaced in any woman of childbearing potential who might conceive. Methyldopa and labetalol are the traditional alternatives.
Check your understanding
Why does an ACE inhibitor raise creatinine at first, and is that a reason to stop the drug?
A patient on amlodipine has new ankle swelling. What is the mechanism and what are the options?
Why is labetalol the usual first-line in a hypertensive emergency?
Multiple choice
Which class lowers blood pressure mainly by dilating arterioles through blockade of L-type calcium channels?
A patient on an ACE inhibitor has a persistent dry cough. What mechanism explains it, and what is the appropriate response?
Which laboratory change is expected and tolerated shortly after starting an ACE inhibitor?
A patient has a hypertensive emergency with acute pulmonary oedema. Which initial treatment is most appropriate?
Which combination should be avoided because the two drugs together risk complete heart block?